Metastatic Pancreatic Cancer Clinical Trials
6 recruiting trials for Metastatic Pancreatic Cancer. Eligibility criteria explained in plain English.
TrialFinderData lists 6 Metastatic Pancreatic Cancer clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Across the trials that carry a phase, Phase 2 is the largest group at 50% (3 studies); the largest phase groups are Phase 2: 3, Phase 1: 1, Phase 1 / Phase 2: 1, Phase 3: 1.
Research is led by National Cancer Institute (NCI) (1), Tianjin Medical University Cancer Institute and Hospital (1), EtiraRx Australia Pty Ltd (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is Pembrolizumab (Keytruda) (drug, 1 trial), followed by Fludarabine, Cyclophosphamide.
Track Metastatic Pancreatic Cancer trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
Background: The NCI Surgery Branch has developed an experimental therapy that involves taking white blood cells from patients' tumors, growing them in the laboratory in large...
QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer
This is a single-center, open-label, exploratory study aims to assess the efficacy and safety of QL1706 plus nab-paclitaxel and gemcitabine as first-line treatment for patients...
A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors
This is a Phase 1 study to assess the safety of ERX-315 in patients with advanced solid tumors that have failed approved systemic therapies.
Trial Evaluating the Efficacy and the Safety of FOLFIRINOX3 Treatment in Patients With Unresectable Locally Advanced or...
Evaluate the efficacy of treatment FOLFORINOX 3 in first-line therapy for patients with locally advanced unresectable or metastatic pancreatic cancer.
Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer
This is an open label study to determine the safety and preliminary evidence of a therapeutic effect of azeliragon in patients refractory to prior treatment of metastatic...
The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer
The aim of this Phase 3 study is to evaluate the efficacy of Kinisoquin™ as compared to the placebo in prevention of thromboembolic events in patients with metastatic or locally...
Explore Other Conditions
Frequently Asked Questions
There are currently 6 clinical trials for Metastatic Pancreatic Cancer, with 6 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Metastatic Pancreatic Cancer, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 1 Phase 3 trials for Metastatic Pancreatic Cancer, representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.